Bristol Myers Squibb to buy Celgene in 74 billion deal
Bristol Myers Squibb agrees to acquire Celgene for 74 billion in cash and stock to expand the combined pipeline with cancer immunology and cardiovascular drugs. The deal adds Revlimid and other near launch products, giving the merged firm nine billion-dollar sales products and existing Orencia and Opdivo portfolios.
MENTIONED IN THIS ARTICLE
Summit
N.J
Bristol- Myers Squibb
Celgene
Bristol
Market Report Shows Dow Closes Higher Near 22,700
Local stocks push gains as the Dow jumps 660.02 to 22,686.22 and Nasdaq gains 202.43 to 6,463.50. Investors monitor shifts in major indices and early trading cues for the week.
MENTIONED IN THIS ARTICLE
Washington
U.S
China
ADP
Peak Smartphone Era Emerges With Diminishing Upgrades
Apple warns weak iPhone demand will tank Q4 revenue, led by China. The broader tech sector faces headwinds as shipments drop, profits shrink, and brands like Samsung, Huawei, Xiaomi, and Oppo compete with newer prices. IDC forecasts a rebound next year but not to 2017 levels.
MENTIONED IN THIS ARTICLE
New York
Apple
China
Dan Ives
Wedbush Securities
Ives
Samsung
U.S
Huawei
Xiaomi
Oppo
International Data Corp
IDC
Zachary Pardes
Fairfield
Connecticut
Also Mentioned on This Page
Bristol-Myers Squibb
Freddie
Mac
The
Associated Press
CMS Energy Corp
Chemical Financial Chfc
Fifth Third Bancorp Fite
Ford Motor Company
General Electric GE
Gentex Corp
GNTX
Huntington Banchban
Illinois Tool Works Inc
ITW
Johnson Controls Jci
Macatawa Bank Corp
MCBC
Magna International Mga
Mercantile Bank Corp
Herman Miller, Inc
MLHR
Perrigo Company Prgo
Pfizer, Inc
PFE
Spartan Nash Sptn
Steelcase Inc. Sci
Tennant Company Tnc
Whirlpool Corp Whr
By Mae Anderson
AP Technology Writer
Brooklyn
Mary Altaffer
Ottawa County Fairgrounds
GateHouse Media
GateHouse Media Publication
America